SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dazzi, F. Articles by Goldman, J. M. Search for Related Content PubMed PubMed Citation Articles by Dazzi, F. Articles by Goldman, J. M. Related Collections Neoplasia Transplantation Immunotherapy Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 October 2000, Vol. 96, No. 8, pp. 2712-2716 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia Francesco Dazzi, Richard M. Szydlo, Nicholas C. P. Cross, Charles Craddock, Jaspal Kaeda, Ed Kanfer, Kate Cwynarski, Eduardo Olavarria, Agnes Yong, Jane F. Apperley, and John M. Goldman From the Department of Haematology, Hammersmith Hospital/ICSM, London, United Kingdom. An analysis was performed of the response to treatment with donor lymphocyte infusions (DLI) and the survival in 66 consecutive patients who relapsed after primary treatment by allogeneic stem cell transplantation for BCR-ABL-positive chronic myeloid leukemia. The transplant donor was an HLA-identical sibling (n = 35) or a "matched" unrelated volunteer (n = 31). Fifty-seven patients were transplanted in chronic phase, eight in accelerated phase, and one in second chronic phase. The recognition of relapse was based on precise molecular, cytogenetic, or hematologic criteria. The median interval from transplant to relapse was 12 months (range 3-85). The median interval from relapse to initiation of DLI was 9.4 months (range 1-70). Patients received DLI from their original transplant donors on a bulk-dose (n = 34) or on an escalating-dose (n = 32) regimen. Patients were monitored serially by hematologic, cytogenetic, and molecular criteria. Molecular remission was defined by the finding of negative results by nested primer reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL transcripts on two consecutive occasions, subject to satisfactory controls. Forty-four patients (67%) achieved molecular remission. Patients who had relapsed to advanced phase disease and patients with short intervals between transplant and relapse had significantly lower probabilities of achieving molecular remission. Of the 44 patients who achieved molecular remission, 4 reverted to a PCR-positive status at 15, 18, 37, and 87 weeks after remission. The probability of survival for patients who achieved molecular remission was significantly better than for those who failed to do so (95% versus 53% at 3 years post-DLI, P = .0001). We conclude that the majority of molecular remissions after DLI are durable, and thus the majority of responding patients may prove to have been cured. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib Blood, January 22, 2009; 113(4): 875 - 882. [Abstract] [Full Text] [PDF] N. S. Majhail Old and New Cancers after Hematopoietic-Cell Transplantation Hematology, January 1, 2008; 2008(1): 142 - 149. [Abstract] [Full Text] [PDF] S. Mackinnon Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337. [Abstract] [Full Text] [PDF] P. Kebriaei, M. A. Detry, S. Giralt, A. Carrasco-Yalan, A. Anagnostopoulos, D. Couriel, I. F. Khouri, P. Anderlini, C. Hosing, A. Alousi, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia Blood, November 1, 2007; 110(9): 3456 - 3462. [Abstract] [Full Text] [PDF] J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone Blood, October 1, 2007; 110(7): 2761 - 2763. [Abstract] [Full Text] [PDF] A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects Blood, July 15, 2007; 110(2): 770 - 775. [Abstract] [Full Text] [PDF] M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF] X.-J. Huang, D.-H. Liu, K.-Y. Liu, L.-P. Xu, H. Chen, and W. Han Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation Haematologica, March 1, 2007; 92(3): 414 - 417. [Abstract] [Full Text] [PDF] T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF] J. Kaeda, D. O'Shea, R. M. Szydlo, E. Olavarria, F. Dazzi, D. Marin, S. Saunders, J. S. Khorashad, N. C. P. Cross, J. M. Goldman, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy Blood, May 15, 2006; 107(10): 4171 - 4176. [Abstract] [Full Text] [PDF] C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT Blood, November 1, 2005; 106(9): 2969 - 2976. [Abstract] [Full Text] [PDF] A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment Mayo Clin. Proc., March 1, 2005; 80(3): 390 - 402. [Abstract] [PDF] M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF] H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF] W. A. Bethge, U. Hegenbart, M. J. Stuart, B. E. Storer, M. B. Maris, M. E. D. Flowers, D. G. Maloney, T. Chauncey, B. Bruno, E. Agura, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Blood, February 1, 2004; 103(3): 790 - 795. [Abstract] [Full Text] [PDF] B. W. Soper, M. D. Lessard, C. D. Jude, A. J. T. Schuldt, R. M. Bunte, and J. E. Barker Successful Allogeneic Neonatal Bone Marrow Transplantation Devoid of Myeloablation Requires Costimulatory Blockade J. Immunol., September 15, 2003; 171(6): 3270 - 3277. [Abstract] [Full Text] [PDF] K. Cwynarski, I. A. G. Roberts, S. Iacobelli, A. van Biezen, R. Brand, A. Devergie, J. M. Vossen, M. Aljurf, W. Arcese, F. Locatelli, et al. Stem cell transplantation for chronic myeloid leukemia in children Blood, August 15, 2003; 102(4): 1224 - 1231. [Abstract] [Full Text] [PDF] M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF] S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation Blood, February 15, 2003; 101(4): 1290 - 1298. [Abstract] [Full Text] [PDF] M.-C. Meunier, G. Roy-Proulx, N. Labrecque, and C. Perreault Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy Blood, January 15, 2003; 101(2): 766 - 770. [Abstract] [Full Text] [PDF] M. J. Robertson, D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson Jr., L. Wood, and K. Cornetta Interleukin 12 Immunotherapy after Autologous Stem Cell Transplantation for Hematological Malignancies Clin. Cancer Res., November 1, 2002; 8(11): 3383 - 3393. [Abstract] [Full Text] [PDF] D. I. Marks, R. Lush, J. Cavenagh, D. W. Milligan, S. Schey, A. Parker, F. J. Clark, L. Hunt, J. Yin, S. Fuller, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood, October 16, 2002; 100(9): 3108 - 3114. [Abstract] [Full Text] [PDF] F. Dazzi, R. M. Szydlo, J. F. Apperley, and J. M. Goldman Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions Blood, September 18, 2002; 100(7): 2673 - 2673. [Full Text] [PDF] C. Guglielmi, W. Arcese, F. Dazzi, R. Brand, D. Bunjes, L. F. Verdonck, A. Schattenberg, H.-J. Kolb, P. Ljungman, A. Devergie, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose Blood, June 28, 2002; 100(2): 397 - 405. [Abstract] [Full Text] [PDF] E. Olavarria, C. Craddock, F. Dazzi, D. Marin, S. Marktel, J. F. Apperley, and J. M. Goldman Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation Blood, May 15, 2002; 99(10): 3861 - 3862. [Abstract] [Full Text] [PDF] J. E. Levine, T. Braun, S. L. Penza, P. Beatty, K. Cornetta, R. Martino, W. R. Drobyski, A. J. Barrett, D. L. Porter, S. Giralt, et al. Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation J. Clin. Oncol., January 15, 2002; 20(2): 405 - 412. [Abstract] [Full Text] [PDF] B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020